Race-specific drugs: regulatory trends and public policy
By David E. Winickoff and Osagie K. Obasogie,
Trends in Pharmacological Sciences
| 06. 04. 2008
Numerous articles and commentaries in the health literature recently have questioned the emergence of race as an increasingly powerful organizing principle in clinical medicine and pharmaceutical development [1,2]. Yet proposals for regulatory reform remain thin. Debate over racebased medicine crystallized around the FDA's June 2005 approval of BiDil, a drug approved to treat African-Americans with heart failure. Some saw BiDil as a dangerous example of marketing trumping science [3], whereas others heralded BiDil as a step towards eliminating racial disparities in health care [4]. One thing is clear: the BiDil debate has left major questions about how clinical trial design and drug regulation should engage this trend [5].
The need for new regulatory approaches to medicines with race-specific indications is growing more acute. A new trend towards designing and conducting clinical trials for race-specific medicines [6] carries serious implications for equitable access to pharmaceutical innovations. Under current policies FDA-approved racial indications might prevent certain groups from accessing certain drugs, even when there is little evidence to warrant such exclusion. Given the stakes of such exclusions for public health, new regulatory...
Related Articles
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...
By Editors, Nature | 08.15.2025
A technology that played a key part in saving millions of lives during the COVID-19 pandemic1 should be feted to the skies. Instead, US health secretary Robert F. Kennedy Jr announced last week that the US federal government is...
By Zusha Elinson, The Wall Street Journal | 08.12.2025
BERKELEY, Calif.—Tsvi Benson-Tilsen, a mathematician, spent seven years researching how to keep an advanced form of artificial intelligence from destroying humanity before he concluded that stopping it wasn’t possible—at least anytime soon.
Now, he’s turned his considerable brainpower to promoting...